Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients

被引:70
|
作者
Francque, Sven M. A. [1 ]
Verrijken, An [2 ]
Mertens, Ilse [2 ]
Hubens, Guy [3 ]
Van Marck, Eric [4 ]
Pelckmans, Paul [1 ]
Michielsen, Peter [1 ]
Van Gaal, Luc [2 ]
机构
[1] Univ Antwerp Hosp, Dept Gastroenterol & Hepatol, Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Diabet Endocrinol & Metab, Antwerp, Belgium
[3] Univ Antwerp Hosp, Dept Abdominal Surg, Antwerp, Belgium
[4] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium
关键词
Risk Factor; Liver Disease; Complication; Genetic Test; Liver Stiffness; SIGNIFICANT FIBROSIS; METABOLIC SYNDROME; HEPATIC STEATOSIS; SCORING SYSTEM; STEATOHEPATITIS; VALIDATION; INDEX; NAFLD; PREDICTION;
D O I
10.1016/j.cgh.2012.06.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Reliable noninvasive tools are needed for staging nonalcoholic fatty liver disease (NAFLD). Published scoring systems have not been validated in prospective assessments of unselected patients. We aimed to identify factors that predicted development of nonalcoholic steatohepatitis (NASH) in a large group of overweight or obese patients and compared these with established factors. METHODS: We performed a prospective analysis of factors associated with the development and severity of NAFLD in patients at a single obesity center. We evaluated liver involvement in 542 patients by a large set of routine and non-routine parameters, including ultrasound and genetic testing. Those suspected of having NAFLD underwent liver biopsy (57.7%). Patients were divided into design cohort (n = 200) and validation cohort (n = 113) to identify factors associated with the presence and severity of NAFLD and NASH. RESULTS: Factors independently associated with development of NASH included increased levels of alanine aminotransferase (ALT), fasting levels of C-peptide, and ultrasound steatosis scores (USSs), with area under the receiver operating curve (AUROC) values of 0.854 in the design cohort and 0.823 in the validation cohort. NASH activity scores also correlated with level of ALT, USS, and fasting level of C-peptide (R-2 = 0.491). Independent predictors of advanced fibrosis included waist circumference and level of aspartate aminotransferase (AUROC values of 0.839 and 0.846 for design and validation cohorts, respectively; negative predictive values of 98% and 97%, respectively, for a cutoff of -2.14). Previously published scoring systems had significantly lower AUROC values. Levels of CK18 and PNPLA3 polymorphisms correlated with development of NASH but did not add value. CONCLUSIONS: Parameters routinely analyzed in assessing obese patients can be used to determine the presence of NASH and advanced fibrosis. Non-routine tests do not increase diagnostic accuracy. Previously published scores are significantly less accurate.
引用
收藏
页码:1162 / 1168
页数:7
相关论文
共 50 条
  • [1] Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
    Castera, Laurent
    Friedrich-Rust, Mireen
    Loomba, Rohit
    GASTROENTEROLOGY, 2019, 156 (05) : 1264 - +
  • [2] Comparative study of overweight and obese patients with nonalcoholic fatty liver disease
    Aller, Rocio
    Burgueno, Beatriz
    Siguenza, Rebeca
    Fernandez-Rodriguez, Conrado
    Fernandez, Natalia
    Antolin, Beatriz
    Dura, Miguel
    Pina, Maria
    Lorenzo, Sara
    Garcia, Concepcion
    de Luis, Daniel A.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (04) : 256 - 263
  • [3] Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Buzzetti, Elena
    Lombardi, Rosa
    De Luca, Laura
    Tsochatzis, Emmanuel A.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [4] Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
    Alexiou, N.
    Giannopoulos, C.
    Mouzakitis, I.
    Skoura, I.
    Sympardi, Styliani
    SCIENTIFIC CHRONICLES, 2018, 23 (02) : 158 - 174
  • [5] Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
    Saleh A. Alqahtani
    Pegah Golabi
    James M. Paik
    Brian Lam
    Amir H. Moazez
    Hazem A. Elariny
    Zachary Goodman
    Zobair M. Younossi
    Obesity Surgery, 2021, 31 : 2002 - 2010
  • [6] Evaluation of adipose tissue and liver radiodensity in overweight or obese patients with nonalcoholic fatty liver disease
    Kempinski, Radoslaw
    Neubauer, Katarzyna
    Halon, Agnieszka
    Podgorski, Przemyslaw
    Dudkowiak, Robert
    Poniewierka, Elzbieta
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2019, 129 (05): : 354 - 356
  • [7] Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
    Bril, Fernando
    Ortiz-Lopez, Carolina
    Lomonaco, Romina
    Orsak, Beverly
    Freckleton, Michael
    Chintapalli, Kedar
    Hardies, Jean
    Lai, Song
    Solano, Felipe
    Tio, Fermin
    Cusi, Kenneth
    LIVER INTERNATIONAL, 2015, 35 (09) : 2139 - 2146
  • [8] Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
    Alqahtani, Saleh A.
    Golabi, Pegah
    Paik, James M.
    Lam, Brian
    Moazez, Amir H.
    Elariny, Hazem A.
    Goodman, Zachary
    Younossi, Zobair M.
    OBESITY SURGERY, 2021, 31 (05) : 2002 - 2010
  • [9] Noninvasive disease severity assessment in nonalcoholic fatty liver disease
    Huang, Jee-Fu
    ADVANCES IN DIGESTIVE MEDICINE, 2023, 10 (02) : 67 - 68
  • [10] Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
    Bernstein, David
    Kovalic, Alexander J.
    METABOLISM OPEN, 2022, 13